RxDoctor Payments DataLook up a doctor →

Lawrence Green, MD

Neurology · Nampa, IDNPI 1386692333

Payments from drug & device makers

$192,696in general payments, 2019–2025

Across 737 payments — averaging $261.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$45K
  • Biogen$38K
  • Genentech USA, Inc.$25K
  • Teva Pharmaceuticals USA, Inc.$24K
  • Lundbeck LLC$23K
  • Bristol Myers Squibb$17K
  • plus $21K from 32 others

What the payments were for

  • Consulting fees$25,05713%
  • Speaking & faculty fees$136,23971%
  • Travel & lodging$18,85810%
  • Food & beverage$12,3186%
  • Education$2240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$192,696 in reported general payments places this provider in the 95th percentile of 59 neurology providers in Idaho.

See all neurology providers in Idaho

Medicare billing

Part B allowed, 2024
$1,148,888
Medicare patients
143
Services billed
20,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide14$129,247
Rebif RebidoseInterferon Beta-1a/Albumin12$121,332
Avonex Pen (4 Pack)Interferon Beta-1a14$110,658
VumerityDiroximel Fumarate12$105,624
Kesimpta PenOfatumumab11$88,814
KeppraLevetiracetam44$64,350
EpidiolexCannabidiol (Cbd)12$44,263
Aimovig AutoinjectorErenumab-Aooe42$38,921
LamictalLamotrigine26$36,173
QuliptaAtogepant29$35,365
Lacosamide195$30,010
Emgality PenGalcanezumab-Gnlm33$29,363
Nurtec OdtRimegepant Sulfate22$26,125
TopamaxTopiramate27$24,249
RytaryCarbidopa/Levodopa41$15,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$6,597$129,24714 claims
BiogenVumerity$38,376$105,62412 claims
AbbVieQulipta$688$35,36529 claims
Amneal Pharmaceuticals LLCRytary$34$15,09141 claims
UCB, Inc.Neupro$142$9,12011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 59 neurology providers in Idaho.

Other neurology in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →